CHATTEM, INC D/B/A OPELLA

Lobbying for CHATTEM, INC D/B/A OPELLA · Healthcare related to nonprescription drugs and dietary supplements.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · New Jersey · House · Senate · $180,000.00 expenses · posted Jul 18, 2025

Lobbying activity 2

Health Issues

Regulatory pathways for OTC drugs and dietary supplements, including OMUFA and Rx to OTC switch.

Consumer Issues/Safety/Products

Retail and cargo theft of medicines, counterfeit and diverted medicines.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.